Stockscreener 앱 받기
22.79
0.70%
-0.16
시간 외 거래:
22.79
전일 마감가:
$22.95
열려 있는:
$23
하루 거래량:
563.36K
Relative Volume:
1.48
시가총액:
$13.37B
수익:
$21.23B
순이익/손실:
$924.30M
주가수익비율:
18.57
EPS:
1.2272
순현금흐름:
$2.22B
1주 성능:
-4.84%
1개월 성능:
-16.09%
6개월 성능:
-21.82%
1년 성능:
+3.12%
1일 변동 폭
$22.73
$23.07
1주일 범위
$22.71
$23.88
52주 변동 폭
$21.42
$30.46
프레제니우스메디칼케어 Stock (FMS) Company Profile
FMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FMS
Fresenius Medical Care Ag Adr
|
22.79 | 13.30B | 21.23B | 924.30M | 2.22B | 1.2272 |
|
HCA
Hca Healthcare Inc
|
481.06 | 109.11B | 74.37B | 7.31B | 8.10B | 25.88 |
|
THC
Tenet Healthcare Corp
|
194.25 | 16.96B | 20.69B | 2.40B | 1.55B | 15.62 |
|
UHS
Universal Health Services Inc
|
227.94 | 14.30B | 16.08B | 1.20B | 1.06B | 17.82 |
|
EHC
Encompass Health Corp
|
111.92 | 11.34B | 5.51B | 494.70M | 386.40M | 4.84 |
프레제니우스메디칼케어 Stock (FMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-09-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2024-12-02 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-11-06 | 개시 | Berenberg | Buy |
| 2024-01-08 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-11-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-17 | 업그레이드 | Societe Generale | Hold → Buy |
| 2023-08-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-01 | 재개 | Citigroup | Neutral |
| 2023-07-12 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | Bernstein | Mkt Perform |
| 2023-01-03 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-10-26 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-10-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-06-27 | 업그레이드 | Jefferies | Underperform → Buy |
| 2022-02-11 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2021-11-23 | 개시 | HSBC Securities | Hold |
| 2021-11-11 | 업그레이드 | Jefferies | Underperform → Hold |
| 2021-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-20 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-06-20 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-26 | 업그레이드 | UBS | Neutral → Buy |
| 2018-08-28 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2018-07-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-01-04 | 업그레이드 | UBS | Sell → Neutral |
| 2017-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2016-11-01 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2016-09-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2016-07-08 | 업그레이드 | Jefferies | Underperform → Hold |
| 2016-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2015-11-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2015-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2015-08-13 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2015-07-31 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2013-08-02 | 재확인 | Feltl & Co. | Hold |
| 2013-01-14 | 업그레이드 | HSBC Securities | Neutral → Overweight |
모두보기
프레제니우스메디칼케어 주식(FMS)의 최신 뉴스
U.S. Arteriovenous Fistula Devices Market Trends Analysis Report 2025-2033: Lucrative Opportunities Stem from Rising ESRD Cases, Driving Demand for AVF Solutions - GlobeNewswire Inc.
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Fresenius Medical Care launches €500 million bond offering - Investing.com India
FMS Stock Price and Chart — NYSE:FMS - TradingView
Diabetes and Well-being: Interview with Dr. Hippen - Fresenius Medical Care
Fresenius Medical Care marks World Diabetes Day 2025: Living well with diabetes and beyond - Fresenius Medical Care
FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y - Finviz
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025 - Fresenius Medical Care
Fresenius Medical Care reports strong Q3 with 8.3% revenue growth - Investing.com
Living well with diabetes and beyond - Fresenius Medical Care
Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025 - Fresenius Medical Care
Fresenius Medical Care Again Named to Top 100 Women-Led Businesses in Massachusetts - Fresenius Medical Care
Research in brief: Time on treatment - Fresenius Medical Care
Bank of America Securities downgrades Fresenius Medical Care AG & Co. KGaA (0H9X) to a Sell - The Globe and Mail
BofA Securities downgrades Fresenius Medical Care stock on volume concerns - Investing.com
Fresenius Medical Care stock rating downgraded to underperform by BofA - Investing.com South Africa
Fresenius Medical Care stock downgraded by BofA on patient volume concerns - Investing.com Nigeria
Fresenius Medical Care Appoints Joseph Turk to Management Board - The Globe and Mail
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement - Fresenius Medical Care
Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment - freseniusmedicalcare.com
Fresenius Medical Care Celebrates Nephrology Nurses Week with The CARE Award - freseniusmedicalcare.com
UBS downgrades Fresenius Medical Care to “sell,” warns on U.S. dialysis outlook - Investing.com
Fresenius Medical Care launches €600 million share buyback tranche - Investing.com
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework - freseniusmedicalcare.com
Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025 - freseniusmedicalcare.com
Fresenius Medical Care ADR earnings beat by $0.41, revenue fell short of estimates - Investing.com Australia
Fresenius Medical Care Q2 results show revenue growth despite challenges - Investing.com
Fresenius Medical Care’s Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care - freseniusmedicalcare.com
Is The Options Market Predicting A Spike In Fresenius Medical Stock? - Barchart.com
"I’m in My Living Life Era”: Katelyn’s Double Transplant Journey - Fresenius Medical Care
Kidney transplantation and value-based care - Fresenius Medical Care
Why I love home dialysis as a HCP working in nephrology - Fresenius Medical Care
Coming Back Home: Dr. Len Usvyat Appointed as the Next Head of the Renal Research Institute - Fresenius Medical Care
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico - freseniusmedicalcare.com
Q2 2025 Media Call - Fresenius Medical Care
Fresenius Medical Care stock holds steady as Truist reiterates $30 target - Investing.com India
Fresenius Medical Care price target raised to €56 on medium-term outlook - Investing.com India
Fresenius Medical Care price target raised to €56 on medium-term outlook By Investing.com - Investing.com South Africa
Bernstein raises Fresenius Medical Care price target on restructuring progress - Investing.com India
프레제니우스메디칼케어 (FMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.12%
자본화:
|
볼륨(24시간):